VKTX Earnings Viking Therapeutics, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–24 of 24
| Q2 2026 | 2026-06-30 | -2.47 | 2026-07-29 | 10-Q |
| Q1 2026 | 2026-03-31 | -1.37 | 2026-04-30 | 10-Q |
| FY 2025 | 2025-12-31 | -3.19 | 2026-02-11 | 10-K |
| Q3 2025 | 2025-09-30 | -1.80 | 2025-10-23 | 10-Q |
| Q2 2026 | 2025-06-30 | -0.99 | 2026-07-29 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.41 | 2026-04-30 | 10-Q |
| FY 2025 | 2024-12-31 | -1.01 | 2026-02-11 | 10-K |
| Q3 2025 | 2024-09-30 | -0.69 | 2025-10-23 | 10-Q |
| Q2 2025 | 2024-06-30 | -0.46 | 2025-07-23 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.26 | 2025-04-24 | 10-Q |
| FY 2025 | 2023-12-31 | -0.91 | 2026-02-11 | 10-K |
| Q3 2024 | 2023-09-30 | -0.66 | 2024-10-23 | 10-Q |
| Q2 2024 | 2023-06-30 | -0.44 | 2024-07-24 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.25 | 2024-04-25 | 10-Q |
| FY 2024 | 2022-12-31 | -0.90 | 2025-02-26 | 10-K |
| Q3 2023 | 2022-09-30 | -0.64 | 2023-10-25 | 10-Q |
| Q2 2023 | 2022-06-30 | -0.43 | 2023-07-26 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.21 | 2023-04-26 | 10-Q |
| FY 2023 | 2021-12-31 | -0.71 | 2024-02-07 | 10-K |
| Q3 2022 | 2021-09-30 | -0.55 | 2022-10-26 | 10-Q |
| Q2 2022 | 2021-06-30 | -0.38 | 2022-07-27 | 10-Q |
| Q1 2019 | 2019-03-31 | -0.07 | 2019-05-02 | 10-Q |
| Q1 2019 | 2018-03-31 | -0.10 | 2019-05-02 | 10-Q |
| Q1 2018 | 2017-03-31 | -0.23 | 2018-05-09 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.